The Axelyf Team
CEO, Co-founder
Chief Counsel, Co-founder
Head of Nanotechnology Formulations
Head of Nucleic Acid Technologies and Biology
Distinguished Advisory Group
Axelyf is supported by experienced advisors spanning the full development pathway for RNA medicines — from regulatory, CMC and clinical pharmacology to computational sciences and nanotechnology. Their collective expertise directly informs Axelyf's platform development and therapeutic programs.
Gabor Butora, PhD – 30 years of pharmaceutical experience in medicinal and process chemistry, including nucleotide chemistry and lipid technologies
Daan Crommelin, PhD – prof. emeritus U. Utrecht in The Netherlands, nanotechnology and protein pharmaceuticals, complex drug product regulatory CMC expert, mRNA product advisor to the WHO
Dan Deaver, PhD – 40+ years academic and industry expertise, in vivo pharmacology, toxicology consultant, including prodrugs, complex injectables
Jóhann E. Guðjónsson, MD, PhD – Arthur C Curtis Prof. of Skin Molecular Immunology, Prof. Dermatology; U. Michigan
Sushma Gurumurthy, PhD – Expert in oncology and immunology drug development including mRNA/LNPs
Magali B. Hickey, PhD – Seasoned Pharmaceutical R&D leader in drug delivery and nanotechnology product development
Eric Jacquinet, DVM, PhD, DABT – pharmacology, toxicology, pathology, preclinical discovery and drug development
Simon Klupfel – expert in AI/ML informatics, ANNA™
Iain McFadyen, PhD – CD(S)O with a proven track record of building, leading, and developing impactful computational sciences and digital systems teams
Arnar Sigurðsson, PhD – protein design and targeting expert

